Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Janet Rader to Middle Aged

This is a "connection" page, showing publications Janet Rader has written about Middle Aged.

 
Connection Strength
  
 
 
1.075
  
  1. Rader JS, Pan A, Corbin B, Iden M, Lu Y, Vellano CP, Akbani R, Mills GB, Simpson P. Identification and validation of a prognostic proteomic signature for cervical cancer. Gynecol Oncol. 2019 11; 155(2):324-330.
    View in: PubMed
    Score: 0.059
  2. Palatnik A, Ye S, Kendziorski C, Iden M, Zigman JS, Hessner MJ, Rader JS. Identification of a serum-induced transcriptional signature associated with metastatic cervical cancer. PLoS One. 2017; 12(8):e0181242.
    View in: PubMed
    Score: 0.051
  3. Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA, Spirtos NM, Byron J, Thaker PH, Lele S, Alberts D. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):291-297.
    View in: PubMed
    Score: 0.050
  4. Liu P, Iden M, Fye S, Huang YW, Hopp E, Chu C, Lu Y, Rader JS. Targeted, Deep Sequencing Reveals Full Methylation Profiles of Multiple HPV Types and Potential Biomarkers for Cervical Cancer Progression. Cancer Epidemiol Biomarkers Prev. 2017 04; 26(4):642-650.
    View in: PubMed
    Score: 0.049
  5. Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013 Jul; 130(1):64-8.
    View in: PubMed
    Score: 0.038
  6. Martin MP, Borecki IB, Zhang Z, Nguyen L, Ma D, Gao X, Qi Y, Carrington M, Rader JS. HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer. Immunogenetics. 2010 Dec; 62(11-12):761-5.
    View in: PubMed
    Score: 0.032
  7. Nugent EK, Case AS, Hoff JT, Zighelboim I, DeWitt LL, Trinkhaus K, Mutch DG, Thaker PH, Massad LS, Rader JS. Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol. 2010 Mar; 116(3):438-41.
    View in: PubMed
    Score: 0.030
  8. Rader JS, Aylsworth CF, Juckett DA, Mutch DG, Powell MA, Lippmann L, Dimitrov NV. Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers. Clin Cancer Res. 2008 May 15; 14(10):3089-97.
    View in: PubMed
    Score: 0.027
  9. Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, Rader JS. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol. 2006 Nov; 103(2):489-93.
    View in: PubMed
    Score: 0.023
  10. Grigsby PW, Watson M, Powell MA, Zhang Z, Rader JS. Gene expression patterns in advanced human cervical cancer. Int J Gynecol Cancer. 2006 Mar-Apr; 16(2):562-7.
    View in: PubMed
    Score: 0.023
  11. Wright JD, Gibb RK, Geevarghese S, Powell MA, Herzog TJ, Mutch DG, Grigsby PW, Gao F, Trinkaus KM, Rader JS. Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer. 2005 Jan 01; 103(1):85-91.
    View in: PubMed
    Score: 0.021
  12. Summey RM, Gornstein E, Decker B, Dougherty KC, Rader JS, Hopp E. Landscape of potential germline pathogenic variants in select cancer susceptibility genes in patients with adult-type ovarian granulosa cell tumors. Cancer Med. 2024 Jun; 13(12):e7340.
    View in: PubMed
    Score: 0.021
  13. Moh M, Puzyrenko A, Summey R, Rader JS, Herrera Cano GE, Gavina JV, Rui H, Sun Y, Hopp E. Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry. Int J Gynecol Pathol. 2024 Sep 01; 43(5):527-534.
    View in: PubMed
    Score: 0.020
  14. Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, Douglass EC. A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol. 2003 Nov; 91(2):318-25.
    View in: PubMed
    Score: 0.020
  15. Gerhard DS, Nguyen LT, Zhang ZY, Borecki IB, Coleman BI, Rader JS. A relationship between methylenetetrahydrofolate reductase variants and the development of invasive cervical cancer. Gynecol Oncol. 2003 Sep; 90(3):560-5.
    View in: PubMed
    Score: 0.019
  16. Wright JD, Horowitz NS, Rader JS. Primary peritoneal carcinoma presenting as adenocarcinoma on a Pap smear. A case report. J Reprod Med. 2002 Nov; 47(11):933-5.
    View in: PubMed
    Score: 0.018
  17. Grigsby PW, Perez CA, Chao KS, Herzog T, Mutch DG, Rader J. Radiation therapy for carcinoma of the cervix with biopsy-proven positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001 Mar 01; 49(3):733-8.
    View in: PubMed
    Score: 0.016
  18. Swisher EM, Babb S, Whelan A, Mutch DG, Rader JS. Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. J Reprod Med. 2001 Feb; 46(2):87-94.
    View in: PubMed
    Score: 0.016
  19. Gagliardi A, Porter VL, Zong Z, Bowlby R, Titmuss E, Namirembe C, Griner NB, Petrello H, Bowen J, Chan SK, Culibrk L, Darragh TM, Stoler MH, Wright TC, Gesuwan P, Dyer MA, Ma Y, Mungall KL, Jones SJM, Nakisige C, Novik K, Orem J, Origa M, Gastier-Foster JM, Yarchoan R, Casper C, Mills GB, Rader JS, Ojesina AI, Gerhard DS, Mungall AJ, Marra MA. Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. Nat Genet. 2020 08; 52(8):800-810.
    View in: PubMed
    Score: 0.016
  20. Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol. 2000 Feb; 76(2):204-7.
    View in: PubMed
    Score: 0.015
  21. Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2019 05; 153(2):335-342.
    View in: PubMed
    Score: 0.014
  22. Harold JA, Uyar D, Rader JS, Bishop E, Nugent M, Simpson P, Bradley WH. Adipose-only sentinel lymph nodes: a finding during the adaptation of a sentinel lymph node mapping algorithm with indocyanine green in women with endometrial cancer. Int J Gynecol Cancer. 2019 01; 29(1):53-59.
    View in: PubMed
    Score: 0.014
  23. Rader JS, Neuman RJ, Brady J, Babb S, Temple S, Kost E, Mutch DG, Herzog TJ. Cancer among first-degree relatives of probands with invasive and borderline ovarian cancer. Obstet Gynecol. 1998 Oct; 92(4 Pt 1):589-95.
    View in: PubMed
    Score: 0.014
  24. Rader JS, Gerhard DS, O'Sullivan MJ, Li Y, Li L, Liapis H, Huettner PC. Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p. Genes Chromosomes Cancer. 1998 May; 22(1):57-65.
    View in: PubMed
    Score: 0.013
  25. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The Immune Landscape of Cancer. Immunity. 2018 04 17; 48(4):812-830.e14.
    View in: PubMed
    Score: 0.013
  26. Liapis H, Adler LM, Wick MR, Rader JS. Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol. 1997 Apr; 28(4):443-9.
    View in: PubMed
    Score: 0.012
  27. Divine LM, Kizer NT, Hagemann AR, Pittman ME, Chen L, Powell MA, Mutch DG, Rader JS, Thaker PH. Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain. Gynecol Oncol. 2016 07; 142(1):76-82.
    View in: PubMed
    Score: 0.012
  28. Kharofa J, Morrow N, Kelly T, Rownd J, Paulson E, Rader J, Uyar D, Bradley W, Erickson B. 3-T MRI-based adaptive brachytherapy for cervix cancer: treatment technique and initial clinical outcomes. Brachytherapy. 2014 Jul-Aug; 13(4):319-25.
    View in: PubMed
    Score: 0.010
  29. Liapis H, Crouch EC, Roby J, Rader JS. In situ localization of parathyroid hormone-like protein and mRNA in intraepithelial neoplasia and invasive carcinoma of the uterine cervix. Hum Pathol. 1993 Oct; 24(10):1058-66.
    View in: PubMed
    Score: 0.010
  30. Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS, Grigsby PW. Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res. 2012 Mar 01; 18(5):1464-71.
    View in: PubMed
    Score: 0.009
  31. Rader JS, Leake JF, Dillon MB, Rosenshein NB. Ultrasonic surgical aspiration in the treatment of vulvar disease. Obstet Gynecol. 1991 Apr; 77(4):573-6.
    View in: PubMed
    Score: 0.008
  32. Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader JS, Mutch DG, Grigsby PW. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011 Mar 01; 117(5):948-56.
    View in: PubMed
    Score: 0.008
  33. Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol. 2011 Jun; 67(6):1225-37.
    View in: PubMed
    Score: 0.008
  34. Rader JS, Haraf DJ, Halpern HJ, Rotmensch J, Spelbring DR, Sutton H, Javaheri G, Weichselbaum RR. Radiation therapy in the treatment of cervical cancer: the University of Chicago/Michael Reese Hospital experience. J Surg Oncol. 1990 Jul; 44(3):157-65.
    View in: PubMed
    Score: 0.008
  35. Hu X, Schwarz JK, Lewis JS, Huettner PC, Rader JS, Deasy JO, Grigsby PW, Wang X. A microRNA expression signature for cervical cancer prognosis. Cancer Res. 2010 Feb 15; 70(4):1441-8.
    View in: PubMed
    Score: 0.008
  36. Zighelboim I, Kizer N, Taylor NP, Case AS, Gao F, Thaker PH, Rader JS, Massad LS, Mutch DG, Powell MA. "Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian cancer. Gynecol Oncol. 2010 Mar; 116(3):370-3.
    View in: PubMed
    Score: 0.008
  37. Showalter TN, Miller TR, Huettner P, Rader J, Grigsby PW. 18F-fluorodeoxyglucose-positron emission tomography and pathologic tumor size in early-stage invasive cervical cancer. Int J Gynecol Cancer. 2009 Nov; 19(8):1412-4.
    View in: PubMed
    Score: 0.007
  38. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutic S, Mutch DG, Powell MA, Grigsby PW. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1085-91.
    View in: PubMed
    Score: 0.007
  39. Kidd EA, Spencer CR, Huettner PC, Siegel BA, Dehdashti F, Rader JS, Grigsby PW. Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer. 2009 Aug 01; 115(15):3548-54.
    View in: PubMed
    Score: 0.007
  40. Nugent EK, Zighelboim I, Case AS, Gao F, Thaker PH, Rader JS, Mutch DG, Massad LS. The value of perioperative imaging in patients with uterine sarcomas. Gynecol Oncol. 2009 Oct; 115(1):37-40.
    View in: PubMed
    Score: 0.007
  41. Zighelboim I, Schmidt AP, Gao F, Thaker PH, Powell MA, Rader JS, Gibb RK, Mutch DG, Goodfellow PJ. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol. 2009 Jul 01; 27(19):3091-6.
    View in: PubMed
    Score: 0.007
  42. Brooks RA, Wright JD, Powell MA, Rader JS, Gao F, Mutch DG, Wall LL. Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. Gynecol Oncol. 2009 Jul; 114(1):75-9.
    View in: PubMed
    Score: 0.007
  43. Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, Broker TR, Meyers C, Chow LT, Zheng ZM. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA. 2009 Apr; 15(4):637-47.
    View in: PubMed
    Score: 0.007
  44. Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, Siegel BA, Grigsby PW. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009 Jan; 112(1):104-9.
    View in: PubMed
    Score: 0.007
  45. Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2008 Dec; 111(3):467-73.
    View in: PubMed
    Score: 0.007
  46. Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2008 Nov-Dec; 18(6):1194-9.
    View in: PubMed
    Score: 0.007
  47. Tierney RM, Powell MA, Mutch DG, Gibb RK, Rader JS, Grigsby PW. Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer. Radiat Med. 2007 Nov; 25(9):439-45.
    View in: PubMed
    Score: 0.007
  48. Wright JD, Grigsby PW, Brooks R, Powell MA, Gibb RK, Gao F, Rader JS, Mutch DG. Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. Cancer. 2007 Sep 15; 110(6):1281-6.
    View in: PubMed
    Score: 0.006
  49. Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res. 2007 Sep-Oct; 27(5B):3525-8.
    View in: PubMed
    Score: 0.006
  50. Wright JD, Grigsby PW, Rader JS, Mutch DG, Powell MA, Gao F, Gibb RK. Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer. Gynecol Oncol. 2007 Nov; 107(2):280-4.
    View in: PubMed
    Score: 0.006
  51. Wright JD, Secord AA, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader JS, Mutch DG. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer. 2008 May-Jun; 18(3):400-6.
    View in: PubMed
    Score: 0.006
  52. Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, Mutch DG. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol. 2007 May 20; 25(15):2042-8.
    View in: PubMed
    Score: 0.006
  53. Lin LL, Mutch DG, Rader JS, Powell MA, Grigsby PW. External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer. Gynecol Oncol. 2007 Jul; 106(1):215-20.
    View in: PubMed
    Score: 0.006
  54. Fayed A, Mutch DG, Rader JS, Gibb RK, Powell MA, Wright JD, Elnaqa I, Zoberi I, Grigsby PW. Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):480-4.
    View in: PubMed
    Score: 0.006
  55. Zighelboim I, Taylor NP, Powell MA, Gibb RK, Rader JS, Mutch DG, Grigsby PW. Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy. Radiat Med. 2006 Nov; 24(9):625-30.
    View in: PubMed
    Score: 0.006
  56. McCourt CK, Mutch DG, Gibb RK, Rader JS, Goodfellow PJ, Trinkaus K, Powell MA. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol. 2007 Mar; 104(3):535-9.
    View in: PubMed
    Score: 0.006
  57. Taylor NP, Powell MA, Gibb RK, Rader JS, Huettner PC, Thibodeau SN, Mutch DG, Goodfellow PJ. MLH3 mutation in endometrial cancer. Cancer Res. 2006 Aug 01; 66(15):7502-8.
    View in: PubMed
    Score: 0.006
  58. Baum ME, Rader JS, Gibb RK, McAlister RP, Powell MA, Mutch DG, Gao F, Wright JD. Colposcopic accuracy of obstetrics and gynecology residents. Gynecol Oncol. 2006 Dec; 103(3):966-70.
    View in: PubMed
    Score: 0.006
  59. Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer. 2006 Jul 01; 107(1):83-9.
    View in: PubMed
    Score: 0.006
  60. Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2006 Nov; 103(2):637-41.
    View in: PubMed
    Score: 0.006
  61. Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006 Oct; 103(1):212-8.
    View in: PubMed
    Score: 0.006
  62. Wright JD, Rader JS, Davila R, Powell MA, Mutch DG, Gao F, Gibb RK. Human papillomavirus triage for young women with atypical squamous cells of undetermined significance. Obstet Gynecol. 2006 Apr; 107(4):822-9.
    View in: PubMed
    Score: 0.006
  63. Wright JD, Rosenbush EJ, Powell MA, Rader JS, Mutch DG, Gao F, Gibb RK. Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery. Gynecol Oncol. 2006 Jul; 102(1):86-91.
    View in: PubMed
    Score: 0.006
  64. Lewin SN, Buttin BM, Powell MA, Gibb RK, Rader JS, Mutch DG, Herzog TJ. Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol. 2005 Nov; 99(2):261-6.
    View in: PubMed
    Score: 0.006
  65. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F, Herzog TJ. Relationship of ovarian neoplasms and body mass index. J Reprod Med. 2005 Aug; 50(8):595-602.
    View in: PubMed
    Score: 0.006
  66. Wright JD, Rosenblum K, Huettner PC, Mutch DG, Rader JS, Powell MA, Gibb RK. Cervical sarcomas: an analysis of incidence and outcome. Gynecol Oncol. 2005 Nov; 99(2):348-51.
    View in: PubMed
    Score: 0.006
  67. Grigsby PW, Mutch DG, Rader J, Herzog TJ, Zoberi I, Siegel BA, Dehdashti F. Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):444-9.
    View in: PubMed
    Score: 0.005
  68. Singh AK, Grigsby PW, Rader JS, Mutch DG, Powell MA. Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):450-5.
    View in: PubMed
    Score: 0.005
  69. Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res. 2004 Nov 01; 10(21):7220-8.
    View in: PubMed
    Score: 0.005
  70. Rutledge TL, Kamelle SA, Tillmanns TD, Gould NS, Wright JD, Cohn DE, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6.
    View in: PubMed
    Score: 0.005
  71. Kamelle SA, Rutledge TL, Tillmanns TD, Gould NS, Cohn DE, Wright J, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol. 2004 Aug; 94(2):249-55.
    View in: PubMed
    Score: 0.005
  72. Wright JD, Powell MA, Herzog TJ, Mutch DG, Rader JS, Gao F, Gibb RK. Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms. Gynecol Oncol. 2004 Aug; 94(2):436-41.
    View in: PubMed
    Score: 0.005
  73. Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I. Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys. 2004 Jul 01; 59(3):706-12.
    View in: PubMed
    Score: 0.005
  74. Sotelo AK, Rader J, Maluf HM. Spindle cell ossifying amyloidotic tumor of the fallopian tube. Int J Gynecol Pathol. 2004 Jul; 23(3):273-7.
    View in: PubMed
    Score: 0.005
  75. Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, Herzog TJ, Rader JS, Gibb RK, Whelan AJ, Goodfellow PJ. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet. 2004 Jun; 74(6):1262-9.
    View in: PubMed
    Score: 0.005
  76. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Huettner PC, Herzog TJ. Synchronous ovarian metastases at the time of laparotomy for colon cancer. Gynecol Oncol. 2004 Mar; 92(3):851-5.
    View in: PubMed
    Score: 0.005
  77. Buttin BM, Powell MA, Mutch DG, Rader JS, Herzog TJ, Gibb RK, Huettner P, Edmonston TB, Goodfellow PJ. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res. 2004 Jan 15; 10(2):481-90.
    View in: PubMed
    Score: 0.005
  78. Armstrong DK, Blessing JA, Rader J, Sorosky JI. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Invest New Drugs. 2003 Nov; 21(4):453-7.
    View in: PubMed
    Score: 0.005
  79. Fracasso PM, Rodriguez LC, Herzog TJ, Fears CL, Goodner SA, Govindan R, Picus J, Rader JS, Tan BR, Arquette MA. Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. Cancer. 2003 Aug 01; 98(3):610-7.
    View in: PubMed
    Score: 0.005
  80. Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, Look K, Walls KC, Fan MY, Mutch DG. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A. 2003 May 13; 100(10):5908-13.
    View in: PubMed
    Score: 0.005
  81. Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL. Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. Ann Oncol. 2002 Nov; 13(11):1819-25.
    View in: PubMed
    Score: 0.005
  82. Horowitz NS, Cohn DE, Herzog TJ, Mutch DG, Rader JS, Bhalla S, Gibb RK. The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. Gynecol Oncol. 2002 Jul; 86(1):79-84.
    View in: PubMed
    Score: 0.004
  83. Whelan AJ, Babb S, Mutch DG, Rader J, Herzog TJ, Todd C, Ivanovich JL, Goodfellow PJ. MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. Int J Cancer. 2002 Jun 10; 99(5):697-704.
    View in: PubMed
    Score: 0.004
  84. Ivanovich J, Babb S, Goodfellow P, Mutch D, Herzog T, Rader J, Whelan A. Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. Clin Cancer Res. 2002 Jun; 8(6):1849-56.
    View in: PubMed
    Score: 0.004
  85. Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer. 2002 Jun 01; 94(11):2941-52.
    View in: PubMed
    Score: 0.004
  86. Horowitz NS, Gibb RK, Menegakis NE, Mutch DG, Rader JS, Herzog TJ. Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients. Obstet Gynecol. 2002 May; 99(5 Pt 1):771-6.
    View in: PubMed
    Score: 0.004
  87. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2002 Apr 01; 20(7):1832-7.
    View in: PubMed
    Score: 0.004
  88. Cohn DE, Dehdashti F, Gibb RK, Mutch DG, Rader JS, Siegel BA, Herzog TJ. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol. 2002 Apr; 85(1):179-84.
    View in: PubMed
    Score: 0.004
  89. Swisher EM, Cohn DE, Goff BA, Parham J, Herzog TJ, Rader JS, Mutch DG. Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol. 2002 Mar; 84(3):363-7.
    View in: PubMed
    Score: 0.004
  90. Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2002 Feb; 84(2):241-4.
    View in: PubMed
    Score: 0.004
  91. Buttin BM, Herzog TJ, Powell MA, Rader JS, Mutch DG. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol. 2002 Jan; 99(1):11-7.
    View in: PubMed
    Score: 0.004
  92. Cohn DE, Mutch DG, Rader JS, Farrell M, Awantang R, Herzog TJ. Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignancies. Gynecol Oncol. 2001 Dec; 83(3):533-6.
    View in: PubMed
    Score: 0.004
  93. O'sullivan MJ, Rader JS, Gerhard DS, Li Y, Trinkaus KM, Gersell DJ, Huettner PC. Loss of heterozygosity at 11q23.3 in vasculoinvasive and metastatic squamous cell carcinoma of the cervix. Hum Pathol. 2001 May; 32(5):475-8.
    View in: PubMed
    Score: 0.004
  94. Cohn DE, Swisher EM, Herzog TJ, Rader JS, Mutch DG. Radical hysterectomy for cervical cancer in obese women. Obstet Gynecol. 2000 Nov; 96(5 Pt 1):727-31.
    View in: PubMed
    Score: 0.004
  95. Cohn DE, Babb S, Whelan AJ, Mutch DG, Herzog TJ, Rader JS, Elbendary A, Goodfellow PJ. Atypical clustering of gynecologic malignancies: A family study including molecular analysis of candidate genes. Gynecol Oncol. 2000 Apr; 77(1):18-25.
    View in: PubMed
    Score: 0.004
  96. Grigsby PW, Perez CA, Chao KS, Elbendary A, Herzog TJ, Rader JS, Mutch DG. Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix Stage IB and IIA treated with preoperative irradiation and surgery. Int J Radiat Oncol Biol Phys. 1999 Oct 01; 45(3):645-51.
    View in: PubMed
    Score: 0.004
  97. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 1997 Sep; 66(3):480-6.
    View in: PubMed
    Score: 0.003
  98. Kowalski LD, Mutch DG, Herzog TJ, Rader JS, Goodfellow PJ. Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer. 1997 Mar; 18(3):219-27.
    View in: PubMed
    Score: 0.003
  99. Leake JF, Rader JS, Woodruff JD, Rosenshein NB. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol. 1991 Aug; 42(2):124-30.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.